Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

NGS-Based Minimal Residual Disease (MRD) after Stem Cell Transplantation (SCT) Is More Specific for Relapse Prediction Than qPCR and Suggests the Possibility of False-Positive qPCR Results

Michaela Kotrova, MD, Vincent H.J. van der Velden, PhD, Jacques J.M. van Dongen, MD PhD, Renata Formankova, MD PhD, Petr Sedlacek, MD PhD, Monika Brüggemann, MD PhD, Jan Zuna, MD PhD, Jan Stary, MD, Jan Trka, MD PhD, Eva Fronkova, M. D., Ph. D.

Blood (2016) 128 (22): 3494.

https://doi.org/10.1182/blood.V128.22.3494.3494

Published: 2016

Journal Articles

Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM)

Bruno Paiva, PhD, Sarah K. Johnson, PhD, Maria-Victoria Mateos, MD PhD, Daisy V. Alapat, MD, Noemi Puig, MD PhD, Miguel-T Hernandez, Fernando Escalante, Alfonso Garcia de Coca, MD PhD, Joan Bladé, Juan Jose Lahuerta, Quentin Lecrevisse, Jacques J.M. van Dongen, MD PhD, Alberto Orfao, MD PhD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD, Jesus San Miguel, MD PhD

Blood (2016) 128 (22): 373.

https://doi.org/10.1182/blood.V128.22.373.373

Published: 2016

Journal Articles

Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)

Blood (2016) 128 (22): 2054.

https://doi.org/10.1182/blood.V128.22.2054.2054

Published: 2016

Journal Articles

High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM)

Paula Arana, Aintzane Zabaleta, Marta Lasa, Patricia Maiso, PhD, Diego Alignani, Tomas Jelinek, MD, Victor Segura, PhD, Wouter van den Bossche, Cristina Teodosio, Daniela Damasceno, Paula Rodriguez-Otero, MD PhD, Felipe Prosper, MD, Maria-Victoria Mateos, MD PhD, Juan Jose Lahuerta, Joan Bladé, Jacques J.M. van Dongen, MD PhD, Jesus San Miguel, MD PhD, Alberto Orfao, MD PhD, Bruno Paiva, PhD

Blood (2016) 128 (22): 482.

https://doi.org/10.1182/blood.V128.22.482.482

Published: 2016

Journal Articles

Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs)

Blood (2016) 128 (22): 801.

https://doi.org/10.1182/blood.V128.22.801.801

Published: 2016

Journal Articles

Late Relapses of Childhood T-ALL Are Frequently Second T-ALL.

Tomasz Szczepanski, MD, PhD, Vincent H.J. van der Velden, PhD, Pieter Van Vlierberghe, Bernd Gruhn, MD, PhD, Renate Panzer-Grumayer, MD, PhD, Monica Spinelli, Helene Cave, PhD, Udo zur Stadt, PhD, Dario Campana, MD, PhD, Andre Schrauder, MD, PhD, Elisabeth van Wering, PhD, Jules P.P. Meijerink, PhD, Jacques J.M. van Dongen, MD, PhD

Blood (2007) 110 (11): 1435.

https://doi.org/10.1182/blood.V110.11.1435.1435

Published: 2007

Journal Articles

Comparative Analysis of Gene Expression Profiles between Diagnosis and Relapse of Childhood Acute Lymphoblastic Leukemia.

Tomasz Szczepanski, MD, PhD, Dick de Ridder, PhD, Vincent H.J. van der Velden, PhD, Tom Schonewille, Elisabeth van Wering, PhD, Jacques J.M. van Dongen, MD, PhD, Frank J.T. Staal, PhD

Blood (2007) 110 (11): 2809.

https://doi.org/10.1182/blood.V110.11.2809.2809

Published: 2007

Journal Articles

Detection of Genomic Lesions in Childhood Precursor-B Cell ALL in Diagnosis and Relapse Samples Using High Resolution Genomic Profiling.

Roland P. Kuiper, PhD, Frank N. van Leeuwen, PhD, Suzanne T.M. Keijzers-Vloet, Simon V. van Reijmersdal, Jayne Y. Hehir-Kwa, Elisabeth R. van Wering, PhD, Vincent H.J. van der Velden, PhD, Jacques J.M. van Dongen, MD/PhD, Eric F.P.M. Schoenmakers, PhD, Ad Geurts van Kessel, PhD, Peter M. Hoogerbrugge, MD/PhD

Blood (2007) 110 (11): 995.

https://doi.org/10.1182/blood.V110.11.995.995

Published: 2007

Journal Articles

Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy.

Roland B. Walter, MD, Ted A. Gooley, PhD, Vincent H.J. van der Velden, PhD, Michael R. Loken, PhD, Jacques J.M. van Dongen, MD/PhD, Irwin D. Bernstein, MD, Frederick R. Appelbaum, MD

Blood (2006) 108 (11): 2324.

https://doi.org/10.1182/blood.V108.11.2324.2324

Published: 2006

NARROW

NGS-Based Minimal Residual Disease (MRD) after Stem Cell Transplantation (SCT) Is More Specific for Relapse Prediction Than qPCR and Suggests the Possibility of False-Positive qPCR Results

Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM)

Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)

High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM)

Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs)

Late Relapses of Childhood T-ALL Are Frequently Second T-ALL.

Comparative Analysis of Gene Expression Profiles between Diagnosis and Relapse of Childhood Acute Lymphoblastic Leukemia.

Detection of Genomic Lesions in Childhood Precursor-B Cell ALL in Diagnosis and Relapse Samples Using High Resolution Genomic Profiling.

Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only